liver cirrhosis
Conditions
Interventions
ciprofol group:Patients in group H received an intravenous injection of nalbuphine at a dose of 0.05 mg/kg (drug concentration: 1 mg/ml, injection time: 10 s ± 5 s) before the endoscopic examination.
Propofol group:P group patients received intravenous injection of 0.05mg/kg nalbuphine (drug concentration 1mg/ml, injection time 10s ± 5s) before endoscopic examination. One minute later, intravenous
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
65 Years to 72 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: (1) Clear diagnosis of liver cirrhosis, with Child-Pugh class A or B; (2) ASA classification of grade I-III, regardless of gender, aged >= 65 years; body mass index (BMI) >= 18 and = 10 and = 95% when breathing air; systolic blood pressure (SBP) >= 90 mmHg; diastolic blood pressure (DBP) >= 60 mmHg; (5) Heart rate >= 60 and <= 100 beats per minute; (6) Have a full understanding of the procedures of this study, be willing to sign the informed consent form, and strictly follow the order as required.
Exclusion criteria
Exclusion criteria: Exclusion criteria: (1) Patients with Child-Pugh class C, a history of clinical hepatic encephalopathy, or those with concurrent mental system diseases, a history of long-term use of psychiatric drugs, and cognitive impairment; (2) Severe lesions of the heart, lungs, kidneys and other systems; (3) Emergency surgery; hypovolemia, shock or coma; (4) Active gastrointestinal bleeding within the past week; (5) Patients allergic to the study drugs; (6) Patients with difficult airways; (7) Those who have been allergic to eggs, beans, opioids and their antidotes, propofol, etc.; (8) Those with contraindications to propofol, opioids and their antidotes; (9) Those who have a history or evidence of cardiovascular diseases, respiratory system diseases, mental and nervous system diseases, etc. that increase the risk during the examination process; (10) Those with a history of asthma, wheezing, sleep apnea syndrome, a history or family history of malignant hyperthermia, or a history of failed tracheal intubation found during the screening period. Those who are judged by the researcher to have a difficult airway during the screening or are determined to have difficulties in tracheal intubation operation (modified Mallampati grade IV) and are at risk of airway management; (11) Those who were found to be research subjects in drug trials within 1 month before screening during the screening period/baseline period, or those who have used lipopropofol, other sedative/anesthetic drugs and/or opioid analgesics or compound preparations containing analgesic ingredients within 72 hours before the baseline; (12) Those with contraindications to routine endoscopic procedures; Subjects for whom the researcher deems there to be any other reasonable reason for not passing the review.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients experiencing adverse cardiopulmonary events; | — |
Countries
China
Contacts
Public ContactNa Qu
Shanghai Public Health Clinical Center
Outcome results
None listed